Xlife Sciences AG / Keyword (s): Regulatory admission / Forecast
Xlife Sciences AG plans to list on the ‘Sparks’ segment of SIX Swiss Exchange
10-Jan-2022 / 06:30 CET / CEST
Disclosure of inside information acc. in Article 17 MAR of Regulation (EU) No 596/2014, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this advertisement.
Xlife Sciences is considering listing on the âSparksâ segment of SIX Swiss Exchange
– Listing on the new “Sparks” segment of SIX Swiss Exchange for small and medium-sized enterprises is scheduled for the first quarter of 2022, subject to the market environment.
– Xlife Sciences AG is a Swiss company focused on developing the value and commercializing promising research projects of universities and other research institutes in the field of life sciences
– The company is involved as an incubator and accelerator in 23 project companies until the successful exit after the proof of concept phase with the aim of participating in their
long-term value development
– Xlife Sciences is currently listed on the Munich Stock Exchange and has a market capitalization of 233 million euros at the end of 2021.
Xlife Sciences AG (XLS DE) confirms its intention to be listed on the SIX Swiss Exchange, as communicated in November 2021. Subject to the market environment, the listing on the new âSparksâ segment of SIX Swiss Exchange is still scheduled for the first quarter of 2022.
Dr. Bernhard Scholz, Chairman of the Board of Xlife Sciences, comments: âSwitzerland has a strong and dynamic life sciences industry and knowledgeable investors and analysts. The new Sparks segment of the Swiss stock exchange is attractive for Xlife Sciences as an emerging growth. company and should further increase our visibility and market transparency. “
Oliver R. Baumann, CEO of Xlife Sciences, added: âWith the planned listing in Switzerland and the accompanying move to a regulated market, we aim to make our business more accessible to institutional investors, to increase the liquidity of the market. ‘action and further improve the transparency of Xlife Sciences. “
Xlife Sciences is a Swiss company focused on developing the value and commercializing promising research projects of universities and other research institutes in the field of life sciences. The aim is to bridge the gap between research and development and healthcare markets.
Xlife Sciences brings carefully selected early stage projects across the four areas of Technology Platforms, Biotechnology / Therapies, Medical Technology and Artificial Intelligence / Digital Health to the next stage of development. The focus is on preclinical biotechnology projects that are successfully acquired by a university, clinical center or research institute. Currently, eleven employees and eight consultants work for Xlife Sciences AG; in all the project companies there are more than 120 scientific staff, researchers and project managers in total.
The Xlife Sciences team has a proven track record in the life sciences industry thanks to the many years of successful partnership expertise of the founders of the company and the Scientific Advisory Board. In addition to Chairman Dr. Bernhard Scholz, the Board of Directors includes Christian Faber, Prof. Dr. Habil. Michael B. Klein, Mark S. MÃ¼ller and Simon SchÃ¶ni. The management team consists of CEO Oliver R. Baumann (also member of the Board of Directors), CFO Carl von Halem, Chief Scientific Officer (CSO) Frank PlÃ¶ger and Beat KlÃ¤ui as Head of Accounting & Taxation .
The value chain
Xlife Sciences generally focuses its involvement in a project on the upstream phase, that is to say until the completion of the so-called âproof of conceptâ phase, and then endeavors to market the project company, for example through a sale of the company or individual product candidates (âcommercial saleâ), through the granting of product licenses or patents, or through an IPO of the project company. This strategy allows Xlife Sciences to achieve an increase in value already after the proof of concept phase. Potential future growth opportunities are also seized with possible milestone payments and royalties in the subsequent market phase.
Xlife Sciences cooperates with 15 leading universities and research institutes in Germany and Switzerland, and examines invention disclosures and project ideas through an in-depth and structured three-step due diligence process. If Xlife Sciences decides to take on the invention disclosure, a separate project company is usually founded for this purpose and prepared for possible exit after a successful proof of concept phase (2-3 years). In addition, these companies are supported in the positioning, structuring and implementation of their concepts, for example by providing management services. In addition, Xlife Sciences aims to create and exploit synergies between the companies in the project.
Currently, Xlife Sciences’ portfolio includes 23 project companies. Five project companies are based in Switzerland, the others mainly in Germany. According to the current assessment of the management team, the project companies Veraxa Biotech, Laxxon Medical, Lysatpharma, Quadira Biosciences, Saniva, Vitruvia, Synimmune, Ix Therapeutics and Baliopharm are among the short and medium term growth drivers of Xlife Science. These growth drivers can be, for example, an exit, the completion of the preclinical development phase, new commitments of federal funds or even the first generation of income.
Listing on the SIX Swiss Exchange
Currently, the company is admitted to trading on the Munich Stock Exchange (unregulated market [“Freiverkehr”] in the m: access segment) with a market capitalization of 233 million euros at the end of 2021. Along with the listing on the SIX Swiss Exchange on the new âSparksâ segment, trading of Xlife Sciences AG shares on the Munich Stock L The exchange will be interrupted for regulatory reasons. The shares will be tradable on SIX Swiss Exchange after the transition to SIX Swiss Exchange.
Following the planned listing on the SIX Swiss Exchange, the proportion of freely negotiable shares (“free float”) should remain at around 44%, the current proportion on the Munich Stock Exchange. The majority of the shares will continue to be held by the two founders as well as the members of the Board of Directors and the management team.
As of October 1, 2021, fast growing small and medium-sized enterprises (SMEs) can be listed on the âSparksâ segment of SIX Swiss Exchange. It is a regulated trading segment adapted to the needs of SMEs and their investors. Among other things, the segment provides easier access for start-ups and a condensed trading window. Apart from this, SMEs are subject to the same prospectus requirements, regulatory oversight and reporting obligations as companies trading on the main segment of SIX Swiss Exchange.
About Xlife Sciences AG
Xlife Sciences is a Swiss company focused as an incubator and accelerator on developing the value and commercializing promising research projects of universities and other research institutes in the life sciences sector, with the aim to provide solutions for unmet medical needs and a better quality of life. The aim is to link research and development to healthcare markets. Xlife Sciences takes carefully selected projects across the four areas of Technology Platforms, Biotechnology / Therapies, Medical Technology and Artificial Intelligence / Digital Health to the next stage of development, and participates in their subsequent performance. For more information, visit www.xlifesciences.ch
This press release may contain “forward-looking statements”, such as directions, expectations, plans, intentions or strategies regarding the future. These forward-looking statements are subject to risks and uncertainties. The reader is warned that actual future results may differ from those expressed or implied by statements, which constitute projections of possible developments. The company assumes no obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
THE INFORMATION CONTAINED IN THIS AD IS FOR CONTEXT PURPOSES ONLY AND IS NOT ENTIRE OR COMPLETE. NO TRUST SHOULD BE PLACED BY ANY PERSON FOR ANY PURPOSE WHETHER THE INFORMATION CONTAINED IN THIS ADVERTISEMENT OR ITS ACCURACY, FAIRNESS OR COMPLETENESS.
THIS INFORMATION DOES NOT CONSTITUTE AN OFFER OR INVITATION TO SUBSCRIBE OR PURCHASE ANY SHARES OR OTHER SECURITIES OF THE COMPANY TO ANY PERSON IN THE UNITED STATES OR IN ANY JURISDICTION FOR WHOM OR SUCH OFFER OR SOLICITATION IS ILLEGAL. IT IS NOT ISSUED IN COUNTRIES WHERE PUBLIC RELEASE OF THE INFORMATION CONTAINED HEREIN MAY BE RESTRICTED OR PROHIBITED BY LAW. DISTRIBUTION OF THIS ADVERTISEMENT MAY BE RESTRICTED BY LAW IN CERTAIN JURISDICTIONS AND PERSONS IN POSSESSION OF ANY DOCUMENT OR OTHER INFORMATION MENTIONED HEREIN SHOULD INFORM AND OBSERVE THIS RESTRICTION. ANY NON-COMPLIANCE WITH THESE RESTRICTIONS MAY CONSTITUTE A VIOLATION OF THE SECURITIES LAWS OF SUCH JURISDICTION. THE SECURITIES OF THE COMPANY ARE NOT AVAILABLE TO THE PUBLIC. THE SECURITIES MENTIONED HEREIN HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE UNITED STATES SECURITIES ACT,
THIS DOCUMENT IS NOT INTENDED TO CONSTITUTE AN OFFER OR SOLICITATION TO PURCHASE OR INVEST IN THE SECURITIES. THE SECURITIES MAY NOT BE OFFERED TO THE PUBLIC, DIRECTLY OR INDIRECTLY, IN SWITZERLAND WITHIN THE MEANING OF THE SWISS FINANCIAL SERVICES ACT (FINSA). NEITHER THIS DOCUMENT NOR ANY OTHER MARKETING MATERIAL RELATING TO THE SECURITIES CONSTITUTES A PROSPECTUS UNDER FINSA OR ANY APPLICABLE LAW OR REGULATION.
10-Jan-2022 CET / CEST DGAP’s distribution services include regulatory announcements, financial / corporate news and press releases.
Archives on www.dgap.de